Harrow Health, Inc. (NASDAQ:HROW) CEO Buys $104,310.00 in Stock

Harrow Health, Inc. (NASDAQ:HROW) CEO Mark L. Baum acquired 9,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now owns 2,137,525 shares of the company’s stock, valued at $24,773,914.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Harrow Health Stock Up 1.2 %

Shares of HROW stock opened at $12.73 on Thursday. The company has a quick ratio of 2.61, a current ratio of 2.83 and a debt-to-equity ratio of 2.60. The firm’s 50-day moving average is $10.66 and its two-hundred day moving average is $11.59. Harrow Health, Inc. has a 12 month low of $7.60 and a 12 month high of $28.25.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HROW shares. B. Riley decreased their price target on shares of Harrow Health from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd. TheStreet downgraded shares of Harrow Health from a “c-” rating to a “d+” rating in a research note on Tuesday, December 12th.

Institutional Investors Weigh In On Harrow Health

Institutional investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC acquired a new stake in shares of Harrow Health during the third quarter valued at about $1,750,000. Jump Financial LLC acquired a new position in shares of Harrow Health in the third quarter valued at approximately $1,038,000. Stifel Financial Corp acquired a new position in shares of Harrow Health in the third quarter valued at approximately $4,887,000. Rice Hall James & Associates LLC acquired a new position in shares of Harrow Health in the third quarter valued at approximately $3,598,000. Finally, Braidwell LP grew its holdings in shares of Harrow Health by 24.5% in the third quarter. Braidwell LP now owns 1,808,684 shares of the company’s stock valued at $25,991,000 after purchasing an additional 356,146 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.